Abstract
To date, the published literature describes 18 reports of nasal septal perforation in cancer patients with the administration of bevacizumab. This complication was detected during post-marketing surveillance of bevacizumab. How should patients who develop this complication be managed? This discussion summarizes suggestions for management of bevacizumab-associated nasal septal perforation and, as relevant to healthcare providers, discusses some of the practical aspects of post-marketing pharmacovigilance.
Original language | English (US) |
---|---|
Pages (from-to) | 307-310 |
Number of pages | 4 |
Journal | Current oncology reports |
Volume | 14 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2012 |
Keywords
- Bevacizumab
- Epistaxis
- Nasal septal perforation
- Pharmacovigilance
ASJC Scopus subject areas
- Oncology